Abstracts tagged "interstitial lung disease"

Abstract Number: 375 • 2018 ACR/ARHP Annual Meeting
Only a Minor Proportion of Individuals with Anti-Aminoacyl-tRNA Synthetase Autoimmunity Presents with the Clinical Picture of “Antisynthetase-Syndrome”
Johannes Knitza, Hannah Schenker, Georg Schett and Jörg Distler, Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Antisynthetase Syndrome is a rare and severe autoimmune inflammatory disease that is associated with autoimmunity against aminoacyl-tRNA synthetase and clinical signs of arthritis, myositis…
Abstract Number: 2422 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Interstitial Lung Disease Related to Autoimmune Disease and Sarcoidosis
Stephanie L. Giattino, Amanda M. Eudy and Megan E. B. Clowse, Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC
Background/Purpose: Currently published data regarding pregnancy outcomes in patients with interstitial lung disease (ILD) related to autoimmune disease and sarcoidosis is limited, with widely variant…
Abstract Number: 384 • 2018 ACR/ARHP Annual Meeting
Patients with Anti-Synthetase Syndrome Have a Similar Prevalence and Severity of Interstitial Lung Disease to Systemic Sclerosis
Bret Sohn¹, Narender Annapureddy², Rosemarie Dudenhofer³, April Barnado¹, Leslie Crofford¹ and Erin Wilfong⁴, ¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁴Division of Rheumatology and Immunology, Vanderbilt Unversity Medical Center, Nashville, TN
Background/Purpose: Interstitial lung disease (ILD) is a significant cause of morbidity and mortality in connective tissue diseases (CTDs). The purpose of this study is to…
Abstract Number: 2708 • 2018 ACR/ARHP Annual Meeting
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
Rebecca B. Blank¹, Jessica K. Gordon², Jackie Szymonifka³, Shervin Assassi⁴, Elana J. Bernstein⁵, Flavia V. Castelino⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique Hinchcliff⁹, Kate Homer¹⁰, Ami A. Shah¹¹, Victoria Shanmugam¹², Virginia D. Steen¹³, Tracy M. Frech¹⁴ and Dinesh Khanna¹⁵, ¹Internal Medicine, New York Presbyterian-Weill Cornell Hospital, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴University of Texas McGovern Medical School, Houston, TX, ⁵Rheumatology, Columbia University, New York, NY, ⁶Rheumatology, Harvard Medical School, Boston, MA, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Northwestern University Medical School, Chicago, IL, ¹⁰Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Rheumatology, The George Washington University, Washington, DC, ¹³Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Standard treatment for the diverse aspects of diffuse cutaneous systemic sclerosis (dcSSc) is not yet well defined although experts have described therapeutic algorithms. The…
Abstract Number: 389 • 2018 ACR/ARHP Annual Meeting
Risk Factors Associated with Mortality in Inflammatory Myositis: An Asian Perspective
Tyng Yu Chuah¹, Yu Heng Kwan², Nai Lee Lui³ and Warren Fong^4,5,6, ¹Department o Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore, ³Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ⁵Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, ⁶Duke-NUS Medical School, Singapore, Singapore
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases with systemic involvement and excess mortality. We aim to describe the causes and…
Abstract Number: 2936 • 2018 ACR/ARHP Annual Meeting
Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis
Silvia Laura Bosello¹, Enrico De Lorenzis¹, Gerlando Natalello², Giovanni Battista Canestrari¹, Laura Gigante¹, Lucrezia Verardi¹, Ludovica Berardini³ and Elisa Gremese¹, ¹Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Rhematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ³Division of Respiratory Medicine, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in Systemic Sclerosis (SSc) but its pathogenesis is not fully understood. Esophageal disease is…
Abstract Number: 525 • 2018 ACR/ARHP Annual Meeting
Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program
Gustavo Citera¹, Eduardo Mysler², Hugo Madariaga³, Mario H Cardiel⁴, Oswaldo Castañeda⁵, Aryeh Fischer⁶, Pascal Richette⁷, Sandra Chartrand⁸, Jin Kyun Park⁹, Sander Strengholt¹⁰, Jose L Rivas¹¹, Amit Thorat¹², Tanya Girard¹³, Kenneth Kwok¹⁴, Lisy Wang¹⁵ and Dario Ponce de Leon¹⁶, ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Clínica del Sur, Arequipa, Peru, ⁴Centro de Investigación Clínica de Morelia, Morelia, Mexico, ⁵Clínica Anglo Americana, Lima, Peru, ⁶Department of Medicine, University of Colorado, Denver, CO, ⁷Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ⁸Department of Medicine, Hôpital Maisonneuve-Rosemont affiliated to Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ¹⁰Pfizer Inc, Capelle aan den IJssel, Netherlands, ¹¹Pfizer SLU, Madrid, Spain, ¹²Pfizer Ltd, Mumbai, India, ¹³Pfizer Inc, Montréal, QC, Canada, ¹⁴Pfizer Inc, New York, NY, ¹⁵Pfizer Inc, Groton, CT, ¹⁶Pfizer Inc, Lima, Peru
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Interstitial lung disease (ILD) is a common extra-articular manifestation of RA,1 and…
Abstract Number: 2979 • 2018 ACR/ARHP Annual Meeting
Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT
Simone Barsotti^1,2, Chiara Romei³, Elisa Cioffi⁴, Claudia Roncella⁵, Elisabetta Perrone³, Alessandra Tripoli¹, Marta Mosca¹, Fabio Falaschi³ and Rossella Neri⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Pisa University Hospital, II Radiology Unit, Pisa, Italy, ⁴Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Pisa University Hospital, I Radiology Unit, Pisa, Italy, ⁶Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Interstitial Lung Disease (ILD) in patients with Idiopathic Inflammatory Myopathies (IIM) is associated to high mortality and morbidity. The study of pleural irregularities (PI)…
Abstract Number: 528 • 2018 ACR/ARHP Annual Meeting
Progression in Interstitial Lung Disease – Comparison of Rheumatoid Arthritis with Idiopathic Pulmonary Fibrosis
Shirish Dubey¹ and Felix Woodhead², ¹Rheumatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ²Respiratory Medicine, Glenfields Hospital, Leicester, United Kingdom
Background/Purpose: Rheumatoid Arthritis (RA) is a common autoimmune condition characterised by symmetrical inflammatory small joint polyarthropathy and loss of function. Systemic manifestations of RA are…
Abstract Number: 791 • 2018 ACR/ARHP Annual Meeting
Safety and Suitability of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Scleroderma-Associated Interstitial Lung Disease (SSc-ILD) Patients
Rick Silver¹, Ilia Atanelishvili², Tanjina Akter², Kelley Kajdasz³, Dulaney Wilson⁴, Paul J. Nietert⁵, J. Terrill Huggins⁶, Kristin B. Highland⁷ and Galina S. Bogatkevich², ¹Rheumatology, Medical University of SC, Charleston, SC, ²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Public Health Sciences, Medical University of South Carolina, Charleston, SC, ⁵Public Health Science, Medical University of South Carolina, Charleston, SC, ⁶Pulmonology, Medical University of South Carolina, Charleston, SC, ⁷Rheumatology.org, Cleveland Clinic, Cleveland, OH
Background/Purpose: Studies from our laboratory and others have shown thrombin to be a fibrogenic mediator implicated in the pathogenesis of ILD, including scleroderma-associated ILD (SSc-ILD).…
Abstract Number: 800 • 2018 ACR/ARHP Annual Meeting
Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
Anna-Maria Hoffmann-Vold¹, Toby Maher², Edward Philpot³, Ali Ashrafzadeh⁴, Diwakar Jha⁵, Margarida Alves⁶ and Oliver Distler⁷, ¹Oslo University Hospital, Oslo, Norway, ²Royal Brompton Hospital, London, United Kingdom, ³IQVIA, Durham, NC, ⁴IQVIA, Los Angeles, CA, ⁵IQVIA, Gurugram, India, ⁶Boehringer Ingelheim International GmbH, Ingelheim, Germany, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of skin and internal organs with an estimated worldwide prevalence of 110-430 cases/million.…
Abstract Number: 2114 • 2017 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?
Sepehr Mesdaghinia¹, Julio Arturo Huapaya², Brainerd Ewarien² and Virginia D. Steen¹, ¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²Medicine, MedStar Georgetown University Hospital, Washington, DC
- Background/Purpose: Interstitial lung disease (ILD) can be an early manifestation of an occult connective tissue disease (CTD). It is important to separate these patients…
Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting
Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama, Ryusuke Yoshimi, Yosuke Kunishita, Daiga Kishimoto, Yohei Kirino and Hideaki Nakajima, Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…
Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama^1,2, Ryusuke Yoshimi^1,2, Maasa Tamura^2,3, Naoki Hamada^1,2, Hideto Nagai^1,2, Naomi Tsuchida^1,4, Yosuke Kunishita^1,2, Yutaro Soejima^1,2, Daiga Kishimoto^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^1,5, Yohei Kirino^1,2, Shigeru Ohno^1,6 and Hideaki Nakajima², ¹Y-CURD Study Group, Yokohama, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Y-CURD Study Group, Yokohma, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Rheumatic Disease Center, Yokohama City University Medical Center, Yokohama, Japan, ⁶Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…
Abstract Number: 2160 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Anti-Aminoacyl tRNA Synthetase Antibodies Which Are Positive By ELISA but Not By Immunoprecipitation – the Variations of Antigen Recognition and the Association with Interstitial Lung Diseases but Not Myositis –
Yuki Ishikawa^1,2, Ran Nakashima¹, Takaki Nojima^3,4, Takuya Isayama⁵, Nobuo Kuramoto¹, Kosaku Murakami¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Clinical Immunology and Rheumatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ³Clinical Immunology and Rheumatolog, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Nojima Internal Medicine Clinic, Hiroshima, Japan, ⁵Medical & Biological Laboratories CO.,LTD., Nagoya, Japan
Background/Purpose: Anti-aminoacyl tRNA synthetase (ARS) antibodies are associated with common clinical characters, which are fever, polyarthritis, interstitial lung disease (ILD), Raynaud’s phenomenon, mechanic’s hand and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].